ConductScience.org, home

Paper34699552

Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.

Hussain Alsayed HA and 5 others. PLoS One, 2021. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study. Papers, record 34699552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34699552

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.
PubMed
Journal
PLoS One
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
1.42
iCite
Revised in PubMed
2024-07-25
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hussain Alsayed HAHawra Ali
2Saheb Sharif-Askari FFatemeh
3Saheb Sharif-Askari NNarjes
4Hussain AASAli Al Sayed
5Hamid QQutayba
6Halwani RRabihhttps://orcid.org/0000-0002-6516-7771

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AlanineMajor topic
Adenosine MonophosphateMajor topic
COVID-19 Drug TreatmentMajor topic
Intensive Care UnitsMajor topic
Antiviral AgentsMajor topic
COVID-19Major topic
Respiration, ArtificialMajor topic
Humans
Male
Female
Retrospective Studies
Middle Aged
Aged
Treatment Outcome
SARS-CoV-2
Hospitalization

Source PubMed

Download CSV of topics

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132706859Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.Clin Infect Dis2021https://conductscience.org/library/papers/32706859PubMed
232020029Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.Cell Res2020https://conductscience.org/library/papers/32020029PubMed
328659436Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.Sci Transl Med2017https://conductscience.org/library/papers/28659436PubMed
432171076Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet2020https://conductscience.org/library/papers/32171076PubMed
532032529Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.Lancet2020https://conductscience.org/library/papers/32032529PubMed
632423584Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet2020https://conductscience.org/library/papers/32423584PubMed
732240634Estimates of the severity of coronavirus disease 2019: a model-based analysis.Lancet Infect Dis2020https://conductscience.org/library/papers/32240634PubMed
831924756Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.Nat Commun2020https://conductscience.org/library/papers/31924756PubMed
932344679The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control.J Clin Med2020https://conductscience.org/library/papers/32344679PubMed
1032445440Remdesivir for the Treatment of Covid-19 - Final Report.N Engl J Med2020https://conductscience.org/library/papers/32445440PubMed
1133631066Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.N Engl J Med2021https://conductscience.org/library/papers/33631066PubMed
1232516797Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.Nature2020https://conductscience.org/library/papers/32516797PubMed
1332678530Dexamethasone in Hospitalized Patients with Covid-19.N Engl J Med2021https://conductscience.org/library/papers/32678530PubMed
1432732352Remdesivir for severe covid-19: a clinical practice guideline.BMJ2020https://conductscience.org/library/papers/32732352PubMed
1533264556Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.N Engl J Med2021https://conductscience.org/library/papers/33264556PubMed
1632187464A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med2020https://conductscience.org/library/papers/32187464PubMed
1732821939Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.JAMA2020https://conductscience.org/library/papers/32821939PubMed
1832253226An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.Sci Transl Med2020https://conductscience.org/library/papers/32253226PubMed
1933099706Revisited COVID-19 Mortality and Recovery Rates: Are we Missing Recovery Time Period?J Med Syst2020https://conductscience.org/library/papers/33099706PubMed

Download CSV of references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42824417Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID-19: A Systematic Review and Meta-Analysis of Retrospective Studies.Health Sci Rep2026https://conductscience.org/library/papers/42824417PubMed
42516643Practical Application of Remdesivir-Based Regimens in COVID-19: A Retrospective Case-Control Analysis.Med J Islam Repub Iran2026https://conductscience.org/library/papers/42516643PubMed
41239269Severe myocardium suppression in two congenital heart disease patients after remdesivir use - a case report.BMC Pediatr2025https://conductscience.org/library/papers/41239269PubMed
40709071Remdesivir Versus Sotrovimab in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.Health Sci Rep2025https://conductscience.org/library/papers/40709071PubMed
38541734Treatment with Remdesivir of Children with SARS-CoV-2 Infection: Experience from a Clinical Hospital in Romania.Life (Basel)2024https://conductscience.org/library/papers/38541734PubMed
38420058Retrospective Cohort Study on Determinants of Mechanical Ventilation Duration of COVID-19 ICU Patients.Cureus2024https://conductscience.org/library/papers/38420058PubMed
38344559Impact of Using Antiviral Therapy on COVID-19 Progression in ICU Patients: A Saudi Arabian Retrospective Analysis.Cureus2024https://conductscience.org/library/papers/38344559PubMed
38339996Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce.J Pediatric Infect Dis Soc2024https://conductscience.org/library/papers/38339996PubMed
38144436The Global Impact of COVID-19: Historical Development, Molecular Characterization, Drug Discovery and Future Directions.Clin Pathol2023https://conductscience.org/library/papers/38144436PubMed
37456740Evaluation of safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study.Front Pharmacol2023https://conductscience.org/library/papers/37456740PubMed
37422621Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study.BMC Infect Dis2023https://conductscience.org/library/papers/37422621PubMed
37304919Bradycardia and Outcomes in COVID-19 Patients on Remdesivir: A Multicenter Retrospective Study.Cardiol Res2023https://conductscience.org/library/papers/37304919PubMed
37243285
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study.
Viruses2023https://conductscience.org/library/papers/37243285PubMed
37048734Mortality, Intensive Care Unit Admission, and Intubation among Hospitalized Patients with COVID-19: A One-Year Retrospective Study in Jordan.J Clin Med2023https://conductscience.org/library/papers/37048734PubMed
36983370Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings.J Clin Med2023https://conductscience.org/library/papers/36983370PubMed
36817340Demographic and clinical characteristics and outcomes of COVID-19 patients admitted to a university hospital in the west of Iran: a retrospective study in the third wave.Vacunas2023https://conductscience.org/library/papers/36817340PubMed
36505104Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan.Cureus2022https://conductscience.org/library/papers/36505104PubMed
36224452Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review.Infection2023https://conductscience.org/library/papers/36224452PubMed
36156891Serum ACE2 Level is Associated With Severe SARS-CoV-2 Infection: A Cross-Sectional Observational Study.Biomark Insights2022https://conductscience.org/library/papers/36156891PubMed
36123499A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjects.Naunyn Schmiedebergs Arch Pharmacol2023https://conductscience.org/library/papers/36123499PubMed

See all 24 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34699552

GET https://conductscience.org/api/papers/v1/34699552/cited_by?page=2